Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy

Donatella Marino, Francesco Leone, Francesca D'Avanzo, Dario Ribero, Lorenzo Capussotti, Massimo Aglietta

Research output: Contribution to journalArticle

Abstract

In recent years, the survival of patients with metastatic disease has improved due to the developments in both medical and surgical care. Patients with technically unresectable metastatic disease could benefit from a multidisciplinary approach for their possible shift toward a technically resectable condition; the choice of the most effective systemic treatment is then crucial to allow conversion to resectability. Systemic conversion therapy may include chemotherapy agents' combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents (cetuximab, panitumumab, bevacizumab). The choice of the best treatment option has to be evaluated by taking into account each patient's baseline characteristics, biological and pathological information and surgical strategy. In particular, the role of some biologic characteristics of the disease, namely the mutational status of EGFR-pathway oncogenes, is emerging as an important predictive factor of response to anti-EGFR targeted agents. Patients presenting with colorectal cancer metastases should be evaluated for multimodal management with curative intent as the appropriate chemotherapy regimen may induce tumor shrinkage, conversion to resectability and improved survival.

Original languageEnglish
Pages (from-to)218-226
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume92
Issue number3
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Colorectal Neoplasms
oxaliplatin
irinotecan
Survival
Therapeutics
Combination Drug Therapy
Oncogenes
Neoplasm Metastasis
Drug Therapy
Neoplasms

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Colorectal cancer metastases
  • Conversion therapy
  • Metastasectomy
  • Resection
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Potentially resectable metastatic colorectal cancer : An individualized approach to conversion therapy. / Marino, Donatella; Leone, Francesco; D'Avanzo, Francesca; Ribero, Dario; Capussotti, Lorenzo; Aglietta, Massimo.

In: Critical Reviews in Oncology/Hematology, Vol. 92, No. 3, 01.12.2014, p. 218-226.

Research output: Contribution to journalArticle

@article{3face873e34e4fa598130fdcb6248ab7,
title = "Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy",
abstract = "In recent years, the survival of patients with metastatic disease has improved due to the developments in both medical and surgical care. Patients with technically unresectable metastatic disease could benefit from a multidisciplinary approach for their possible shift toward a technically resectable condition; the choice of the most effective systemic treatment is then crucial to allow conversion to resectability. Systemic conversion therapy may include chemotherapy agents' combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents (cetuximab, panitumumab, bevacizumab). The choice of the best treatment option has to be evaluated by taking into account each patient's baseline characteristics, biological and pathological information and surgical strategy. In particular, the role of some biologic characteristics of the disease, namely the mutational status of EGFR-pathway oncogenes, is emerging as an important predictive factor of response to anti-EGFR targeted agents. Patients presenting with colorectal cancer metastases should be evaluated for multimodal management with curative intent as the appropriate chemotherapy regimen may induce tumor shrinkage, conversion to resectability and improved survival.",
keywords = "Chemotherapy, Colorectal cancer, Colorectal cancer metastases, Conversion therapy, Metastasectomy, Resection, Targeted therapies",
author = "Donatella Marino and Francesco Leone and Francesca D'Avanzo and Dario Ribero and Lorenzo Capussotti and Massimo Aglietta",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.critrevonc.2014.05.010",
language = "English",
volume = "92",
pages = "218--226",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Potentially resectable metastatic colorectal cancer

T2 - An individualized approach to conversion therapy

AU - Marino, Donatella

AU - Leone, Francesco

AU - D'Avanzo, Francesca

AU - Ribero, Dario

AU - Capussotti, Lorenzo

AU - Aglietta, Massimo

PY - 2014/12/1

Y1 - 2014/12/1

N2 - In recent years, the survival of patients with metastatic disease has improved due to the developments in both medical and surgical care. Patients with technically unresectable metastatic disease could benefit from a multidisciplinary approach for their possible shift toward a technically resectable condition; the choice of the most effective systemic treatment is then crucial to allow conversion to resectability. Systemic conversion therapy may include chemotherapy agents' combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents (cetuximab, panitumumab, bevacizumab). The choice of the best treatment option has to be evaluated by taking into account each patient's baseline characteristics, biological and pathological information and surgical strategy. In particular, the role of some biologic characteristics of the disease, namely the mutational status of EGFR-pathway oncogenes, is emerging as an important predictive factor of response to anti-EGFR targeted agents. Patients presenting with colorectal cancer metastases should be evaluated for multimodal management with curative intent as the appropriate chemotherapy regimen may induce tumor shrinkage, conversion to resectability and improved survival.

AB - In recent years, the survival of patients with metastatic disease has improved due to the developments in both medical and surgical care. Patients with technically unresectable metastatic disease could benefit from a multidisciplinary approach for their possible shift toward a technically resectable condition; the choice of the most effective systemic treatment is then crucial to allow conversion to resectability. Systemic conversion therapy may include chemotherapy agents' combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents (cetuximab, panitumumab, bevacizumab). The choice of the best treatment option has to be evaluated by taking into account each patient's baseline characteristics, biological and pathological information and surgical strategy. In particular, the role of some biologic characteristics of the disease, namely the mutational status of EGFR-pathway oncogenes, is emerging as an important predictive factor of response to anti-EGFR targeted agents. Patients presenting with colorectal cancer metastases should be evaluated for multimodal management with curative intent as the appropriate chemotherapy regimen may induce tumor shrinkage, conversion to resectability and improved survival.

KW - Chemotherapy

KW - Colorectal cancer

KW - Colorectal cancer metastases

KW - Conversion therapy

KW - Metastasectomy

KW - Resection

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84912558470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912558470&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2014.05.010

DO - 10.1016/j.critrevonc.2014.05.010

M3 - Article

C2 - 24985058

AN - SCOPUS:84912558470

VL - 92

SP - 218

EP - 226

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -